Diabetes Type 2 Clinical Trial
Official title:
A Randomized, Double-blind, Placebo-controlled Study of the Effect of Mineralocorticoid Receptor Antagonists in Type 2 Diabetes Patients on Myocardial Function, Glucose and Fat Metabolism (The MIRAD-study)
The aim of this study is to investigate the effect of selective blocking of the mineralocorticoid receptor in patients with type 2 diabetes on insulin resistance, lipid metabolism and myocardial function.
In this randomized, double-blind, placebo-controlled study we want to investigate the effect
of mineralocorticoid receptor antagonists in type 2 diabetes patients on myocardial function,
glucose and fat metabolism.
Background The mortality rate in T2 DM is still increased by almost a factor 2 although poly
pharmacological therapy of risk factors has been recommended for years. Treatment with MR
antagonists in patients with primary hyperaldosteronism and systolic heart failure improves
insulin resistance, myocardial function and prognosis. Further, recent evidence has suggested
that aldosterone participates in the regulation of glucose and lipid metabolism, as MR
expression has been identified in adipocytes and beneficial metabolic effects of selective MR
blockade has been demonstrated in several animal models. Notably, there is no available data
in humans with T2DM.
A key feature of T2 DM is altered body composition characterized by increased metabolic
active visceral adipose tissue (VAT) and increased fat content of the liver, which has been
associated with cardiac dysfunction and outcome. Gold standard for measurement of VAT is
magnetic resonance imaging (MRI), and proton MRI spectroscopy can quantitatively measure fat
content in the liver with high precision. The pathogenesis of myocardial dysfunction in T2DM
is linked with insulin resistance (IR) of adipose tissue mediating increased supply of free
fatty acids and intra myocardial lipid accumulation. Thus, beneficial effects of lipid
metabolism could in theory indirectly improve myocardial function in type 2 diabetics.
Global longitudinal strain (GLS) is a validated method for evaluating regional and global
function of the left ventricle, which is a strong predictor of incident HF in patients with
myocardial infarction and closely related with plasma NT-proBNP concentrations.
Hypothesis Selective blocking of the MR receptor in patients with T2 DM improves insulin
resistance, lipid metabolism and myocardial function.
Objectives To investigate the effect of Eplerenone 100-200 mg once daily compared to placebo
in patients with type 2 diabetes with regard to glucose and lipid metabolism, myocardial
function and structure, and vascular function.
The primary objective is to investigate the effect of Eplerenone 100-200 mg once daily
compared to placebo on changes in liver fat content.
Design A single center, randomized, double blinded placebo controlled trial. Patients with T2
DM and high risk of cardiovascular disease will be randomized to either Eplerenone 100-200 mg
or placebo daily for 26 weeks. Patients will be investigated at baseline and after 26 weeks.
A total of 130 patients with type 2 diabetes will be included.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Active, not recruiting |
NCT04954313 -
Baseline Oral Health Study: UnCoVer the Connections to General Health
|
Phase 4 | |
Completed |
NCT01354925 -
Management of Type-2 Diabetic Patients Treated With Insulin During the Ramadan
|
Phase 4 | |
Completed |
NCT01206725 -
Exercise Study on Cardiac Function in Patients With Diabetes Mellitus Type 2 and Diastolic Dysfunction
|
N/A | |
Completed |
NCT00997282 -
A Study of OPC-262 in Patients With Type 2 Diabetes
|
Phase 2/Phase 3 | |
Completed |
NCT00637546 -
Gait and Balance of Diabetes Type 2 Patients
|
Phase 2/Phase 3 | |
Completed |
NCT00464880 -
Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02057497 -
An Exploratory Clinical Trial to Generate Whole Blood Samples for Analysing Genetic Polymorphisms
|
N/A | |
Active, not recruiting |
NCT05014204 -
Safety and Feasibility of Novel Therapy for Duodenal Mucosal Regeneration for Type II Diabetes
|
N/A | |
Recruiting |
NCT03662217 -
Personalized Nutrition for Diabetes Type 2
|
N/A | |
Completed |
NCT04276051 -
Cryovagotomy Diabetes Trial
|
N/A | |
Completed |
NCT02569684 -
Effects of Prebiotics on GLP-1 in Type 2 Diabetes
|
N/A | |
Active, not recruiting |
NCT01933529 -
ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)
|
Phase 2 | |
Terminated |
NCT01722474 -
Assessment of Three Instruments for the Non-invasive Measurement of Arterial Stiffness.
|
N/A | |
Completed |
NCT00977262 -
Postprandial Inflammation and Fatty Acids
|
N/A | |
Completed |
NCT00518427 -
Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine
|
Phase 4 | |
Recruiting |
NCT05378620 -
Project Dulce for Filipino-Americans With Type 2 Diabetes
|
N/A | |
Recruiting |
NCT03834207 -
A Study of the Usefulness & Usability of a Healthcare IT System for Managing Multi-morbidity and Poly-pharmacy
|
N/A | |
Active, not recruiting |
NCT05228067 -
Enhancing Brain Health by tDCS in Persons With Overweight and Obesity
|
N/A | |
Active, not recruiting |
NCT05689684 -
Arabinoxylan-oligosaccharides (AXOS) for the Management of Type-2 Diabetes
|
N/A |